Ospedale Vito Fazzi Lecce
- Address
- lock Available on a paid plan
Ospedale Vito Fazzi Lecce - Comprehensive Oncology and Hematology Research Center
Ospedale Vito Fazzi Lecce is a leading clinical research institution with extensive expertise in hematologic malignancies and solid tumor oncology. The center demonstrates particular strength in conducting complex trials for leukemias, lymphomas, and advanced-stage cancers, with a focus on innovative targeted therapies and immunotherapeutic approaches.
- Acute and chronic leukemias including AML, ALL, CML, and CLL with minimal residual disease monitoring
- Lymphomas (Hodgkin's, follicular, diffuse large B-cell, and mantle cell lymphoma)
- Advanced solid tumors including metastatic colorectal, breast, lung, ovarian, cervical, pancreatic, and renal cancers
- Pediatric hematology-oncology including juvenile idiopathic arthritis and childhood leukemias
The center's research portfolio encompasses cutting-edge therapeutic strategies including novel antibody-drug conjugates, BCL-2 and BTK inhibitors, immune checkpoint inhibitors, and CAR-T cell therapies. With significant experience in both early-phase dose-finding studies and large-scale Phase III randomized trials, Ospedale Vito Fazzi Lecce actively contributes to international collaborative networks, advancing treatment protocols for high-risk patient populations including those undergoing hematopoietic stem cell transplantation and patients with treatment-refractory disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 199 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 189 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 33 by active trials.
lock +32 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale Vito Fazzi Lecce
lock Showing 1 of 78 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 199 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 11 | Unknown | 2018-07-15 | 2024-10-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.